Abbott Laboratories (NYSE:ABT) Receives $119.09 Average Price Target from Analysts

Abbott Laboratories (NYSE:ABT) has been given a consensus recommendation of “Moderate Buy” by the twenty-six analysts that are covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $119.0870.

A number of equities research analysts have recently weighed in on ABT shares. Oppenheimer cut their price target on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Daiwa Securities Group cut Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target on the stock. in a report on Wednesday, April 22nd. Sanford C. Bernstein cut their price target on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Royal Bank Of Canada cut their price target on Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Finally, Jefferies Financial Group cut their price target on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a report on Friday, April 17th.

Abbott Laboratories Stock Performance

ABT opened at $90.71 on Friday. The business’s 50 day moving average is $93.07 and its 200-day moving average is $109.44. The stock has a market cap of $157.99 billion, a PE ratio of 25.41, a price-to-earnings-growth ratio of 1.45 and a beta of 0.63. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $139.06.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The company had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. This trade represents a 0.15% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Philip P. Boudreau purchased 2,200 shares of the firm’s stock in a transaction on Thursday, April 23rd. The shares were purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the purchase, the chief financial officer owned 2,200 shares in the company, valued at $201,300. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.46% of the company’s stock.

Hedge Funds Weigh In On Abbott Laboratories

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ABT. J. Stern & Co. LLP boosted its stake in Abbott Laboratories by 12,439.6% during the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares in the last quarter. Norges Bank bought a new position in Abbott Laboratories during the 4th quarter valued at $2,938,892,000. Invesco Ltd. increased its holdings in shares of Abbott Laboratories by 51.0% in the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock valued at $1,868,718,000 after buying an additional 4,713,135 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Abbott Laboratories by 217.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 5,522,222 shares of the healthcare product maker’s stock valued at $566,967,000 after buying an additional 3,780,402 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in shares of Abbott Laboratories by 303.0% in the first quarter. Assenagon Asset Management S.A. now owns 4,429,571 shares of the healthcare product maker’s stock valued at $454,784,000 after buying an additional 3,330,368 shares in the last quarter. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.